AlzeCure Pharma arranged a Capital Markets Day on May 17 with Professor Bengt Winblad as an invited guest speaker.
The aim of the day was to present the developments of AlzeCure’s Alzheimer’s projects Alzstatin and NeuroRestore. Professor Bengt Winblad from Karolinska Institutet also participated, giving an update on the positive developments in the Alzheimer field. The presentations was followed by a moderator-led Q&A session where there was an opportunity to submit questions.
Presenters from AlzeCure are CEO Martin Jönsson, Dr. Pontus Forsell, Head of Discovery & Research and Dr. Johan Sandin, Chief Scientific Officer.
The Capital Markets Day took place in collaboration with FinWire, https://www.finwire.tv/webcast/alzecure-pharma/presentation-17-maj/.
Program:
10:00 Welcome address & agenda – Martin Jönsson, CEO, AlzeCure
10:02 AlzeCure Pharma: Overview, vision & update – Martin Jönsson, CEO, AlzeCure
10:10 Alzheimer’s disease, societal challenges & recent developments in the field – Professor Bengt Winblad, M.D., PhD, Karolinska Institute
10:25 Alzstatin: Background & evolution – Johan Sandin, PhD, CSO, AlzeCure
10:45 NeuroRestore: Background & data supporting disease modifying effects – Pontus Forsell, PhD, Head of Discovery & Research, AlzeCure
11:05 Panel discussion & QnA – Lead by Martin Westerberg, FinWire
11:25 Concluding remarks – Martin Jönsson, CEO, AlzeCure
